Japan Approves Leqembi Pen for At-Home Alzheimer’s Treatment

The approval marks a significant shift in how early-stage Alzheimer’s disease is managed in Japan. Unlike the existing intravenous formulation, which requires a clinical setting every two weeks, the subcutaneous pen allows for two weekly injections totaling 500 mg. Each dose takes approximately 15 seconds to administer, potentially streamlining the treatment pathway while maintaining efficacy comparable to the traditional IV method. Data from clinical trials indicates that the safety profiles remain largely consistent between the two delivery methods, with systemic injection-related reactions occurring in only 1.4% of cases under the subcutaneous regimen.

Eisai, the partner of Swedish firm BioArctic AB in this development, noted that the transition to at-home administration is intended to lower barriers for patients seeking to initiate or maintain therapy. While the move offers greater flexibility, the Japanese health authorities maintain strict safety protocols. Initial doses must be administered by or under the direct supervision of a physician, with self-administration permitted only after patients and caregivers complete comprehensive training. Regular monitoring via magnetic resonance imaging remains a requirement to track amyloid-related imaging abnormalities, ensuring that the shift to home care does not compromise patient safety standards.